Overview:

Summary

“Will 2011 Spell a Brighter Year for the Pharmaceutical Companies?” provides information on the 2011 pharmaceutical industry scenario and the factors that will shape and drive the industry in 2011. This report features approval trends, R&D spend and important features of major therapeutic areas. The report also highlights the pipeline features of major pharmaceutical and biotechnology companies.

Scope

- Learn about the prospective drug approvals in 2011
- Understand pharma R&D strategies
- Get an insight into the pipeline highlights in major therapy areas
- Pipeline activity of some pharmaceutical majors

Reasons to buy

- Understand the approval trends over the last three years
- Get an insight into the prospective drug approvals of 2011
- Obtain an understanding of the factors influencing R&D expenditure and the focus of major pharmaceutical companies
- Develop entry strategies to further design product development, marketing and sales strategies

1 Table of Contents 1
1.1 List of Figures 1
2 Summary 1
3 Pharma R&D Strategies 2
4 Prospective Approvals in 2011 2
5 Pipeline Focus 2
5.1 Pipeline Highlights in Major Therapy Areas 2
5.1.1 Oncology 3
5.1.2 Central Nervous System (CNS) 3
5.1.3 Infectious Diseases 3
5.1.4 Cardiovascular and Metabolic Disorders 3
5.1.5 Respiratory Disorders 3
5.2 Pipeline Activity of Some Pharmaceutical Majors 4
5.2.1 GSK 4
5.2.2 Pfizer 4
5.2.3 Sanofi-Aventis 4
5.2.4 AstraZeneca 4
5.2.5 Merck 4
5.2.6 Novartis 4
5.2.7 Bristol-Myers Squibb (BMS) 5
5.2.8 Eli Lilly 5
5.2.9 Johnson & Johnson (J&J) 5
5.3 Conclusion 5
6 Appendix 5
6.1 Methodology 5
6.1.1 Coverage 5
6.1.2 Secondary Research 5
6.1.3 Primary Research 6
6.1.4 Expert Panel Validation 6
6.2 Contact Us 6
6.3 Disclaimer 6

1.1 List of Figures
Figure 1: Approval Trends Graph - 2008, 2009, 2010 1
Figure 2: Pharma R&D Spend 2
Figure 3: Therapy Area Focus 2
Figure 4: Therapy Area Focus by Clinical Development 3
Figure 5: Pipeline Projects 4